Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022).

"We have been able to show a correlation between patient survival and a measure of the cumulative potency of PROVENGE; such a correlation between product potency and clinical outcome has not been previously demonstrated with an active immunotherapy," said Mark Frohlich, MD, chief medical officer of Dendreon. "These data provide further evidence that sipuleucel-T is actively engaging the immune system in a clinically meaningful way that prolongs patient survival."

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease. Currently, there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... YORK , Dec. 18, 2014 Somewhere ... addressing hearing health was forgotten. But Audicus , ... to hear better this new year. Hearing ... facing the aging population, though it is often unaddressed. ... in four has a hearing aid, mainly due to ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... , INDIANAPOLIS, Aug. 10 Acquire ... fabrication and integration and automation services, has recently expanded ... in its focus on a long-term goal of becoming ... North America. , , Acquire Automation ...
... SEATTLE, Aug. 7 Regular yoga practice is associated ... to be obese, according to a study led by researchers at ... study was prompted by initial findings reported four years ago by ... may help prevent middle-age spread in normal-weight people and may promote ...
Cached Medicine Technology:Vision Inspection Systems Specialist Acquire Automation Expands Employee Base, Launches New Web Site 2Regular Yoga Practice Is Associated With Mindful Eating 2Regular Yoga Practice Is Associated With Mindful Eating 3Regular Yoga Practice Is Associated With Mindful Eating 4
(Date:12/19/2014)... Rosa, CA (PRWEB) December 19, 2014 ... and 5x5 SuperClone Rooms. SuperCloset continues to offer indoor ... solutions. Pair one of the new SuperClone Rooms with ... professional, perpetual, and turnkey indoor hydroponic grow room setup. ... in the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... These vanadium reserves are mostly found in ... tons of vanadium were produced globally in 2013, up ... at 6.7% AAGR during the period from 2001 to ... the largest consumer, accounted for more than 90% of ... and the chemical industry. , View Full Report at ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- New research warns parents that buying ... at risk. Nearly half of teen drivers killed in the ... at least 11 years old and often lacked important safety features ... percent of teen drivers killed in crashes were in cars at ... 10 years old, 31 percent were in cars 11 to 15 ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- All children should have ... 6, preferably every year, eye experts say. The ... expert panel of the U.S. National Center for Children,s ... this age group require screening for eye problems, particularly ... as amblyopia ("lazy eye") and strabismus (a disorder of ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Preschoolers Need Eye Screening, Experts Say 2
... ... year old Mitchell Brown ( www.helpmitchell.com ), an athlete, loving young father, and lifetime resident of ... months before the birth of his second child. , ... East Brunswick, NJ (Vocus) September 3, 2009 -- The race is on to find ...
... goal, researchers say , THURSDAY, Sept. 3 (HealthDay News) -- ... to cooperate, researchers at Harvard University and the Stockholm School ... a stick. , In certain situations "where people interact ... our work suggests that rewards result in better outcomes than ...
... , BROOMFIELD, Colo., Sept. 3 Embla(R) and ... acquire Covidien,s Sleep Diagnostic business. This includes the sleep diagnostic products ... transaction were not disclosed. Completion of the sale is subject to ... will form the world,s largest company to focus entirely on sleep ...
... Unanimous Decision on Med Mal, Negligence, and TAPA Claims , ... favor of the estate of Mrs. Voncil Sherrod, who died on 3/24/05 ... Rehabilitation, a Mariner Health Care nursing home in Tennessee. Counsel for ... of the firm Marks, Balette & Giessel, P.C. and Matthew Mussalli. , ...
... China, Sept. 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the ... D, Rule 504 offering and is no longer selling shares ... will be filed with the Securities and Exchange Commission shortly, ... over the past twelve months. The limit to any such ...
... Ga., Sept. 3 Aflac Incorporated (NYSE: AFL ) ... Bruyette, & Woods 2009 Insurance Conference. Chairman and Chief Executive ... scheduled to make a presentation on September 10, 2009, at 2:05 ... discuss the company,s outlook for 2009 and its strategy for growth ...
Cached Medicine News:Health News:Jewish Stem Cell Donor Urgently Sought for Young NJ Man Battling Aggressive Non-Hodgkin Lymphoma 2Health News:Jewish Stem Cell Donor Urgently Sought for Young NJ Man Battling Aggressive Non-Hodgkin Lymphoma 3Health News:Rewards Are Key to Cooperation 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2Health News:Arbitration Panel Finds in Favor of Tennessee Victim of Mariner Nursing Home Negligence 2Health News:Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering 2Health News:Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering 3Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2009 Insurance Conference 2
... Used for stone manipulation and removal in ... the basket to retain its shape following extreme ... stone capture by allowing the basket to open ... the stone. The tipless design reduces the likelihood ...
... Perc NCircle® is designed to provide rapid ... The Perc NCircle combines traditional surgical instrument ... tipless basket technology. The small, flexible ... allows the surgeon to remove larger stones ...
... Used for temporary internal drainage ... bladder. Supplied sterile in peel-open packages. ... evaluation is advised; C-Flex® and Sof-Flex® ... than six (6) months; silicone stents ...
... ACMI Classic Double Pigtail Ureteral ... pigtail design that maximizes migration. They ... added versatility and cost savings. ... Kit contains one Classic Double PigTail ...
Medicine Products: